Sensydia has raised approximately $8 million in new funding led by Florida-based Orlando Health Ventures, with participation from Colle Capital, Frontier Venture Capital, and others.
This funding will enable the company to finalize the development of its groundbreaking non-invasive cardiac assessment platform, Cardiac Performance System (CPS™), and submit to the United States Food and Drug Administration (FDA) in 2024 for prioritized review as part of the FDA Breakthrough Devices Program.
Sensydia continues to push the boundaries of its heart-sound AI technology, which promises to transform the diagnosis and management of heart disease, the leading cause of death worldwide.
We are thrilled to have the support of investors who share our vision for transforming heart failure management. This funding will enable us to accelerate our march to commercialization by expanding development and operations for our CPS platform.Anthony Arnold, President and CEO of Sensydia
Concurrent with this financing, Erick Hawkins, Chief Administrative Officer for Orlando Health, will join the Sensydia board of directors.
“Sensydia’s CPS technology is a game-changing AI application that makes crucial cardiac data both accessible and affordable,” said Victoria Grace, Founder of Colle Capital and Sensydia Board Member. “This technology transcends geographical and financial barriers to care, unlocking new markets while enhancing early diagnosis and treatment protocols.”
Sensydia’s CPS platform uses ultra-sensitive biosensors and AI algorithms to provide clinicians with rapid, non-invasive measurement of ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure in a handheld device without the need for in-hospital catheterization.
“Non-invasive and real-time cardiac function measures will lead to early diagnosis and personalized care for heart disease,” said Farhan Khawaja, MD, President of the Orlando Health Heart & Vascular Institute. “This technology has the potential to vastly improve patient lives by enabling faster and more affordable disease management, moving healthcare from the hospital setting into the patient’s home.”